Dr. Reddy’s collaborates with Sanofi India for an Exclusive distribution partnership

About the Partnership

In a significant move aimed at enhancing healthcare accessibility in India, Dr. Reddy’s, a leading pharmaceutical company based in India, has unveiled an exclusive partnership with Sanofi Healthcare India Private Limited (SHIPL) for the distribution of Sanofi’s vaccine brands across private markets in the country.

Under the terms of this exclusive arrangement, Dr. Reddy’s will hold the sole rights to promote and distribute a range of Sanofi’s well-established pediatric and adult vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel, and Avaxim 80U. These brands, renowned for their efficacy and trustworthiness, collectively accounted for sales of approximately Rs 426 crores (around USD 51 million) as per IQVIA MAT February 2024. While Dr. Reddy’s will spearhead the promotion and distribution efforts, Sanofi will retain ownership and oversee manufacturing and importation processes for these brands in India.

Stock Performance

In the last trading session, the company’s stock closed at Rs 6,126.95. Opening at Rs 6,150 today, the stock closed at Rs 6,052.50, reflecting a 1.22% decrease. The company’s 52-week high stands at Rs 6,505.50, while its 52-week low stands at Rs 4,383.40. The company currently boasts a market capitalization of approximately Rs 1,00,900 crore. Over the past year, shares have delivered a return of 34.92%, while the BSE Healthcare index saw changes of 59.51% during the same period.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing access to affordable and innovative medicines. The company offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC medications. Its major therapeutic areas of focus include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Major markets include the USA, India, Russia & CIS countries, China, Brazil, and Europe. With a history of pioneering scientific advancements, the company continues to plan ahead and invest in businesses of the future.

Disclaimer: This blog is intended solely for educational purposes. The securities mentioned are for illustrative purposes only and not recommendations. The content is sourced from various secondary sources on the internet and is subject to change. Please consult with a financial expert before making any related decisions.